(PRWEB) September 06, 2012
SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today the release of its first brochure for patients and caregivers about life with the SynCardia temporary Total Artificial Heart.
“By providing this brochure, we hope to address many of the common questions asked by patients and their families,” said Michael Garippa, SynCardia Chairman/CEO/President. ”Implanting the Total Artificial Heart isn’t just a medical decision made by surgeons; it is also a family decision made by patients with the help of their loved ones. We want them to feel confident when making this vital decision about their medical care and their lives.”
The 12-page brochure was produced in a format that mimics the size and shape of an iPad. Readers learn about the progression of heart failure, the shortage of donor hearts and the role of the SynCardia Total Artificial Heart as a bridge to transplant. It also describes how the Total Artificial Heart works and what patients should expect before surgery, after the implant and during recovery.
In addition, the brochure introduces readers to the drivers that power the Total Artificial Heart. This section includes a checklist titled, “When Can I Go Home?” which provides an overview of the steps that need to be completed in order for patients to be discharged from the hospital to wait for a matching donor heart at home and in their communities using the Freedom® portable driver.
Weighing 13.5 pounds, the Freedom driver is the world’s first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.
Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
SynCardia Wins Two Gold Stevies® at 2012 American Business Awards
On June 18, 2012, SynCardia was honored with two Gold Stevie® Awards at the 10th Annual American Business Awards. SynCardia won "Company of the Year – Health Products and Services" and "Most Innovative Company of the Year – up to 100 Employees." See the full list of SynCardia Awards & Recognition, which includes accolades from Forbes, Fast Company and more.